PF-04950615
Phase 1Biologic
PfizerPF-04950615 is one of 37 biologic programs targeting Hypercholesterolemia. It is currently in Phase 1.
1
Indications
6
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
130 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Lescol
NovartisPhase 3
Micardis
Boehringer IngelheimPhase 3
Comparator: Statins
Merck & Co.Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Evacetrapib
Eli LillyPhase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Enlicitide
Merck & Co.Phase 3
Anacetrapib
Merck & Co.Phase 3
Lapaquistat Acetate
TakedaPhase 3
Bococizumab
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cholesterol2 trials
Statins2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-04950615. EMBL-EBI & Wellcome Sanger Institute.
- [4]